{"id":"placebo-with-clozapine","safety":{"commonSideEffects":[{"rate":"0.5-1%","effect":"Agranulocytosis"},{"rate":"20-40%","effect":"Sedation"},{"rate":"20-30%","effect":"Weight gain"},{"rate":"10-20%","effect":"Orthostatic hypotension"},{"rate":"10-25%","effect":"Tachycardia"},{"rate":"1-2%","effect":"Seizures"},{"rate":"<1%","effect":"Myocarditis"},{"rate":"10-30%","effect":"Hypersalivation"}]},"_chembl":{"chemblId":"CHEMBL1688","moleculeType":"Small molecule","molecularWeight":"342.83"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=placebo with Clozapine","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T07:17:51.256675+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T07:18:06.324160+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T07:17:56.751204+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=placebo with Clozapine","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T07:17:57.051797+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1688/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T07:17:58.106158+00:00"}},"_dailymed":null,"aiSummary":"Placebo with Clozapine, marketed by the Shanghai Mental Health Center, holds a niche position in the psychiatric treatment landscape. The key composition patent expires in 2028, providing a period of exclusivity that supports current market presence. The primary risk is the lack of clear primary indication and revenue data, which may limit strategic planning and market expansion efforts.","mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clozapine antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors, reducing hyperactivity in mesolimbic and mesocortical pathways associated with psychosis. It also has activity at multiple other receptors including muscarinic, histaminergic, and adrenergic receptors, which contribute to its therapeutic and adverse effects. The combination with placebo in this context likely refers to a clinical trial design comparing clozapine efficacy against placebo control.","oneSentence":"Clozapine is an atypical antipsychotic that blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:32.222Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T07:18:06.324231+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Schizophrenia, particularly treatment-resistant cases"},{"name":"Schizoaffective disorder"},{"name":"Reduction of suicidal behavior in schizophrenia"}]},"trialDetails":[{"nctId":"NCT07326124","phase":"PHASE3","title":"Stratification and Treatment in Early Psychosis Study -ASSIST","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2026-06","conditions":"Treatment Resistant Psychosis, Psychosis","enrollment":250},{"nctId":"NCT06174116","phase":"PHASE4","title":"Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia","status":"RECRUITING","sponsor":"University of Massachusetts, Worcester","startDate":"2024-04-02","conditions":"Schizophrenia, Schizo Affective Disorder","enrollment":50},{"nctId":"NCT05944510","phase":"PHASE4","title":"Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2023-08-31","conditions":"Treatment Resistant Schizophrenia","enrollment":40},{"nctId":"NCT06906224","phase":"EARLY_PHASE1","title":"Effects of Buspirone Combined With Clozapine","status":"COMPLETED","sponsor":"Chuanfu Song","startDate":"2022-05-01","conditions":"Schizophrenia","enrollment":46},{"nctId":"NCT04892199","phase":"PHASE4","title":"Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anders Fink-Jensen, MD, DMSci","startDate":"2021-09-01","conditions":"Metabolic Disturbance, Schizophrenia, Type 2 Diabetes","enrollment":104},{"nctId":"NCT02640300","phase":"PHASE4","title":"Switching Antipsychotics: Abrupt Discontinuation Versus Overlap","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"1999-05","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":33},{"nctId":"NCT03652974","phase":"PHASE4","title":"Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2018-09-06","conditions":"Schizophrenia","enrollment":145},{"nctId":"NCT03094429","phase":"PHASE2, PHASE3","title":"An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults","status":"RECRUITING","sponsor":"SyneuRx International (Taiwan) Corp","startDate":"2017-03-29","conditions":"Refractory Schizophrenia","enrollment":287},{"nctId":"NCT03565068","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-20","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT02181803","phase":"PHASE1","title":"MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-08-05","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT01567124","phase":"PHASE4","title":"Alleviating the Metabolic Side Effects of Antipsychotic Medications","status":"WITHDRAWN","sponsor":"Baker Heart and Diabetes Institute","startDate":"2012-05","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT00690235","phase":"PHASE4","title":"Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-11","conditions":"Schizophrenia, Schizoaffective Disorder, Diabetes","enrollment":33},{"nctId":"NCT00981526","phase":"PHASE4","title":"Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2009-03","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":66},{"nctId":"NCT00882856","phase":"NA","title":"Treating Clozapine-induced Sinustachycardia With Bisoprolol","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2009-04","conditions":"Clozapine-induced Sinustachycardia","enrollment":21},{"nctId":"NCT02751307","phase":"PHASE4","title":"Adjunctive Low-dose Metformin in Patients With Schizophrenia and Metabolic Abnormalities","status":"COMPLETED","sponsor":"Taipei Medical University WanFang Hospital","startDate":"2013-05","conditions":"Metabolic Syndrome","enrollment":55},{"nctId":"NCT00158223","phase":"PHASE4","title":"Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2004-10","conditions":"Schizophrenia, Psychotic Disorders","enrollment":76},{"nctId":"NCT01246232","phase":"PHASE4","title":"Amisulpride Augmentation in Clozapine-unresponsive Schizophrenia","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2011-09","conditions":"Schizophrenia","enrollment":69},{"nctId":"NCT00345033","phase":"PHASE4","title":"Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2005-03","conditions":"Schizophrenia, Insulin Resistance","enrollment":38},{"nctId":"NCT00000372","phase":"PHASE3","title":"Glycine and D-Cycloserine in Schizophrenia","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"1998-03","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT01323205","phase":"PHASE2","title":"Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-05","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT02049021","phase":"PHASE4","title":"Electroconvulsive Therapy (ECT) in Patients With Super Refractory Schizophrenia","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2010-02","conditions":"Refractory Schizophrenia, Super Refractory Schizophrenia","enrollment":20},{"nctId":"NCT00289861","phase":"PHASE4","title":"Risperidone Augmentation in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2003-02","conditions":"Schizophrenia","enrollment":24},{"nctId":"NCT00216281","phase":"PHASE3","title":"Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia","status":"TERMINATED","sponsor":"Indiana University School of Medicine","startDate":"2005-09","conditions":"Schizophrenia","enrollment":126},{"nctId":"NCT01401491","phase":"PHASE4","title":"Treatment Strategy for Refractory Schizophrenia: Drug Interaction Between Clozapine and Fluvoxamine","status":"COMPLETED","sponsor":"Taipei Medical University Hospital","startDate":"2008-01","conditions":"Schizophrenia","enrollment":80},{"nctId":"NCT01279213","phase":"PHASE4","title":"Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia","status":"COMPLETED","sponsor":"Universidad Nacional de Rosario","startDate":"2009-01","conditions":"Schizophrenia, Schizophrenic Disorders, Psychotic Disorder","enrollment":70},{"nctId":"NCT00918021","phase":"PHASE4","title":"Polypharmacy in Clozapine-resistant Schizophrenia","status":"COMPLETED","sponsor":"Niuvanniemi Hospital","startDate":"2009-06","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":30},{"nctId":"NCT00345982","phase":"NA","title":"Augmenting Clozapine With Sertindole - SERCLOZ","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2006-09","conditions":"Schizophrenia","enrollment":50},{"nctId":"NCT01015001","phase":"PHASE3","title":"A Pilot Double-blind Sham-controlled Trial of Repetitive Transcranial Magnetic Stimulation for Patients With Refractory Schizophrenia Treated With Clozapine","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2008-05","conditions":"Schizophrenia, Auditory Hallucinations","enrollment":20},{"nctId":"NCT01105481","phase":"PHASE4","title":"Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2006-05","conditions":"Treatment-resistant Schizophrenia","enrollment":273},{"nctId":"NCT00573417","phase":"PHASE4","title":"A Placebo-Controlled Trial of Modafinil (Provigil) Added to Clozapine in Patients With Schizophrenia","status":"COMPLETED","sponsor":"North Suffolk Mental Health Association","startDate":"2003-09","conditions":"Schizophrenia","enrollment":40},{"nctId":"NCT00235352","phase":"PHASE2, PHASE3","title":"Trial of Ampakine Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia","status":"COMPLETED","sponsor":"North Suffolk Mental Health Association","startDate":"2002-02","conditions":"Schizophrenia","enrollment":105},{"nctId":"NCT00757978","phase":"PHASE4","title":"Memantine as Adjunctive Therapy for Schizophrenia Negative Symptoms","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2006-01","conditions":"Schizophrenia","enrollment":22},{"nctId":"NCT00328367","phase":"PHASE4","title":"Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2005-12","conditions":"Schizophrenia","enrollment":61}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL1688"},"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"placebo with Clozapine","genericName":"placebo with Clozapine","companyName":"Shanghai Mental Health Center","companyId":"shanghai-mental-health-center","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T07:18:06.324231+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}